Bioverativ Inc (NASDAQ:BIVV)’s share price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $104.32 and last traded at $103.91, with a volume of 1267000 shares trading hands. The stock had previously closed at $103.91.
BIVV has been the topic of several analyst reports. Zacks Investment Research raised Bioverativ from a “hold” rating to a “buy” rating and set a $60.00 price objective on the stock in a research report on Monday, January 1st. Jefferies Group upped their price objective on Bioverativ to $79.00 and gave the company a “buy” rating in a research report on Thursday, January 18th. Morgan Stanley raised Bioverativ from an “underweight” rating to an “equal weight” rating in a research report on Tuesday, January 23rd. Deutsche Bank set a $53.00 price objective on Bioverativ and gave the company a “hold” rating in a research report on Monday, November 20th. Finally, Argus reaffirmed a “hold” rating on shares of Bioverativ in a research report on Wednesday, January 24th. Thirteen investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $63.15.
The company has a market capitalization of $11,380.00 and a P/E ratio of 38.23.
Bioverativ (NASDAQ:BIVV) last announced its earnings results on Tuesday, February 13th. The biotechnology company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01. The business had revenue of $328.70 million during the quarter, compared to analyst estimates of $325.89 million. Bioverativ had a net margin of 30.43% and a return on equity of 40.99%. equities analysts forecast that Bioverativ Inc will post 3.83 EPS for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. raised its stake in Bioverativ by 16.9% during the 4th quarter. BlackRock Inc. now owns 10,845,635 shares of the biotechnology company’s stock valued at $584,795,000 after buying an additional 1,567,638 shares during the last quarter. Old Mutual Global Investors UK Ltd. raised its stake in Bioverativ by 47.8% during the 4th quarter. Old Mutual Global Investors UK Ltd. now owns 2,507,002 shares of the biotechnology company’s stock valued at $135,177,000 after buying an additional 810,364 shares during the last quarter. Wells Fargo & Company MN purchased a new stake in Bioverativ during the 3rd quarter valued at $124,500,000. Jackson Square Partners LLC raised its stake in Bioverativ by 21.1% during the 4th quarter. Jackson Square Partners LLC now owns 2,107,110 shares of the biotechnology company’s stock valued at $113,615,000 after buying an additional 366,503 shares during the last quarter. Finally, Woodford Investment Management Ltd purchased a new stake in Bioverativ during the 3rd quarter valued at $85,455,000. Institutional investors and hedge funds own 99.97% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Bioverativ (BIVV) Sets New 12-Month High at $104.32” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/24/bioverativ-bivv-sets-new-12-month-high-at-104-32.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.